Study summary · 2020 · Randomized trial
OSICAT: a neutral primary result in heart-failure monitoring
Telemonitoring did not significantly improve the primary composite endpoint.
Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence
Original publication
Telemonitoring versus standard care in heart failure: a randomised multicentre trial
Michel Galinier; François Roubille; Philippe Berdague; Gilles Brierre; Philippe Cantie; Patrick Dary; Jean-Marc Ferradou; Olivier Fondard; Jean Philippe Labarre; Jacques Mansourati; François Picard; Jean-Etienne Ricci; Muriel Salvat; Lamia Tartière; Jean-Bernard Ruidavets; Vanina Bongard; Cécile Delval; Guila Lancman; Hélène Pasche; Juan Fernando Ramirez-Gil; Atul Pathak; OSICAT Investigators
French hospital and cardiology centers; INSERM; Air Liquide Santé International; Princess Grace Hospital, Monaco
European Journal of Heart Failure · Online: · Issue: June 2020
Journal version of record. · Full text consulted.
What was studied
- Design
- Randomized trial
- Population
- Adults hospitalized for acute HF within the preceding year
- Sample
- 937 analyzed participants (990 enrolled)
- Intervention
- Daily weight/symptom monitoring with education
- Comparator
- Standard care
- Follow-up
- 18 months
- Setting
- France; 38 centers
Methods
Open-label multicenter randomized trial.
Findings
For all-cause death or unplanned hospitalization events, the rate ratio was 0.97 (95% CI 0.77–1.23; P=.80). Adjusted secondary and subgroup findings were more favorable.
Limitations
The analysis excluded 53 of 990 enrolled patients after randomization; 632 completed 18 months. This modified evaluable population and incomplete follow-up complicate interpretation. Favorable secondary or adherence analyses do not overturn the neutral primary result.
What this means for care delivery
A credible evidence review should include neutral trials when describing likely program benefits.